Vetoquinol (XPAR:VETO) Cyclically Adjusted PS Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:VETO Vetoquinol SA XPAR:VETO
91 GF Score
Price €73.60
GF Value €80.88
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Vetoquinol Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Vetoquinol  (XPAR:VETO) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Vetoquinol Cyclically Adjusted PS Ratio Related Terms


Vetoquinol Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Vetoquinol's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vetoquinol Cyclically Adjusted PS Ratio Chart

Vetoquinol Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.05 2.43 2.63 1.83 1.98

Vetoquinol Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.32 1.83 1.77 1.98 1.63

XPAR:VETO vs ZTS, UTHR, VTRS: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vetoquinol's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vetoquinol Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vetoquinol's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Vetoquinol's Cyclically Adjusted PS Ratio falls into.


XPAR:VETO
91GF Score
Vetoquinol SA XPAR:VETO
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vetoquinol Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Vetoquinol's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec25 is calculated as:

For example, Vetoquinol's adjusted Revenue per Share data for the fiscal year that ended in Dec25 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec25 (Change)*Current CPI (Dec25)
=45.232/120.8900*120.8900
=45.232

Current CPI (Dec25) = 120.8900.

Vetoquinol Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201612 29.555 100.650 35.498
201712 29.703 101.850 35.256
201812 31.074 103.470 36.306
201912 33.468 104.980 38.540
202012 36.146 104.960 41.632
202112 44.072 107.850 49.401
202212 45.622 114.160 48.312
202312 44.730 118.390 45.675
202412 45.711 119.950 46.069
202512 45.232 120.890 45.232

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Vetoquinol (XPAR:VETO) Overvalued in 2026?

Based on GuruFocus' analysis, Vetoquinol stock appears to be undervalued. The current stock price of €73.60 is trading 9% below its estimated GF Value™ of €80.88. GuruFocus considers Vetoquinol to be Fairly Valued.

Key valuation signals for XPAR:VETO:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €80.88 vs. price of €73.60 (9% below fair value)
  • GF Score™: 91/100 with 1 warning sign

No single metric tells the full story. See the XPAR:VETO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vetoquinol Business Description

Other Exchanges 0O1O:UK8JM:Germany
Address Magny-Vernois, BP 189, Lure cedex, FRA, 70204
Vetoquinol SA operates is a France-based firm serving in the healthcare market. Its focus lies on developing and marketing veterinary drugs mainly in the European region and to a certain extent in America and Asia. Its portfolio of drugs entails anti-infectives, anti- pain inflammatory drugs, cardiovascular and nephrology treatment intended mainly for pets and livestock.
91GF Score

Get the complete analysis for XPAR:VETO

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€73.60
Price
€80.88
GF Value